BODIPY-based fluorescent probe for selective detection of HSA in urine. (January 2022)

• Record Type: Journal Article
• Authors: Xu, Hui; Shen, Guohua; Peng, Cheng; Han, Xiumin; Duan, Liping; Cheng, Tanyu
• Is Part Of: Dyes and pigments. Volume 197(2022)
• Publication Date: 2022-01
• Subjects: Fluorescence -- BODIPY -- HSA -- Human urine; Dyes and dyeing -- Periodicals; Pigments -- Periodicals; 667.2
• DOI: 10.1016/j.dyepig.2021.109915
• Languages: English
• ISSNs: 0143-7208

Abstract

Abstract: Quantitative recognition of human serum albumin (HSA) is of great importance in the fields of biology and biomedicine. In biological fluids, HSA has been used as an important biomarker for disease early diagnosis. For example, microalbuminuria has been regarded as an early indicator of diabetic nephropathy. Therefore, it is of great significance to monitor HSA in urine. In this work, a BODIPY-based fluorescence probe, BDY-OH, was constructed for HSA detection, which showed a high signal to noise ratio and high selectivity. In addition, plot of fluorescence intensity exhibited a 90-fold enhancement and a good linear correlation from 0 mg/mL to 0.4 mg/mL. Encouraged by the outstanding properties, the ability of BDY-OH to distinguish proteinuria from normal urine was tested among 39 clinical urine samples and the excellent recognition rate of 89.7% suggested a great significance for the early diagnosis of kidney related diseases. We look forward to using the BDY-OH method as a new tool for preclinical diagnosis of HSA in urine in the future. Highlights: A BODIPY-based fluorescence probe BDY-OH for human serum albumin (HSA) was developed. The probe BDY-OH exhibited ultrahigh selectivity towards HSA. The response of the probe BDY-OH to HSA exhibited a detection limit as low as 1.89 mg/L. The probe BDY-OH was successfully used to distinguish proteinuria in urine samples with a recognition rate of 89.7%.